Investors
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
The Vaxart Value Proposition
Vaxart’s leaders and scientists explain how the little pill that moves the needle can have a significant impact on global public health.
Latest News
October 24, 2024
October 15, 2024
September 30, 2024
Events
August 08, 2024 at 4:30 PM EDT
May 13, 2024 at 4:30 PM EDT
March 14, 2024 at 4:30 PM EDT
